Purpose To identify quantitative imaging biomarkers at fluorine 18 (18F) positron emission
tomography (PET) for predicting distant metastasis in patients with early-stage non–small …

Purpose To determine whether quantitative imaging features from pretreatment positron
emission tomography (PET) can enhance patient overall survival risk stratification beyond …

Purpose The objective of this study was to determine the accuracy of (early) response
measurements using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography …

The integral role of positron-emission tomography (PET) using the glucose analog tracer
fluorine-18 fluorodeoxyglucose (FDG) in the staging of non-small cell lung cancer (NSCLC) …

AIM To assess the prognostic value of 2-[18 F]-fluoro-2-deoxy-d-glucose (FDG) positron-
emission tomography (PET)-based radiomics using a machine learning approach in patients …

Purpose Our objective was to determine the impact of initial 18 F-FDG PET/CT (PET/CT)
staging on clinical stage and the management plan and the prognostic value of PET/CT in …

For several years, molecular imaging with 18F‐fluorodeoxyglucose positron emission
tomography (FDG‐PET) has become part of the standard of care in presurgical staging of …

Background Lymph node stage prior to treatment is strongly related to disease progression
and poor prognosis in non-small cell lung cancer (NSCLC). However, few studies have …

Survival of lung cancer patients remains poor despite increasingly aggressive treatment.
Conventional staging has well-described limitations. 18F-FDG PET has been shown to …

Purpose In this prospective National Cancer Institute–funded American College of
Radiology Imaging Network/Radiation Therapy Oncology Group cooperative group trial, we …